“The realm and the role of the bioscience sector are rapidly changing, creating new opportunities for small start-ups and biotechs. In particular, as large pharmaceutical companies downsize their R&D workforce in response to pricing and regulatory pressures, they seek to invest in and/or acquire smaller companies and focus their efforts on product marketing, sales, and distribution. For example, to bolster its pipeline, Cubist acquires Trius and Optimer, smaller companies with antibiotic products, and Merck has taken over Idenix (admittedly no longer a “small” biotech company, but the model holds). For many of these large pharmaceutical companies, acquiring smaller or start-up biotechnology companies provides support for their own development efforts as their older products lose patent protection.” (Froshauer S., 2017)
Reference
Froshauer S. (2017). Careers at biotech start-ups and in entrepreneurship. Cold Spring Harbor Perspectives in Biology,9(11), a032938. https://doi.org/10.1101/cshperspect.a032938.
Q1: Which of the following sample best utilizes summarization of the case?
- A. As an alternative to launching new products, bigger companies tend to acquire small companies which have shown to be more cost effective and convenient in the biotech industry. (Froshauer S. 2017)
- B. Merck took over Idenix to grow further in the biotech industry (Froshauer S. 2017)
- C. Cubist acquires Trius and Optimer as a way to increase product portfolio (Froshauer S. 2017)